Biosimilars And Obamacare's Shadow: Zarxio Appeals Key On Legislative Intent
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen and Sandoz both emphasize differences between biosimilars statute and Hatch-Waxman Act in effort to get en banc review at Federal Circuit.